ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(S)-オメプラゾールナトリウム塩

Esomeprazole Sodium

HCID 23674541
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
161796-78-7
標準SMILES
COc1ccc2[n-]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]
InChIKey
RYXPMWYHEBGTRV-JIDHJSLPSA-N
分子式
C17H18N3NaO3S
平均分子量
367.4 g/mol
単同位体質量
367.0966569

概要

Esomeprazole Sodium is the sodium salt of the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.

名称と識別子

優先名称
Esomeprazole Sodium
IUPAC
sodium 5-methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide
現地名
(S)-オメプラゾールナトリウム塩
英語名
Esomeprazole sodium
分子式
C34H36MgN6O6S2
分子量
368.41

名称と別名

Esomeprazole Sodium161796-78-7Nexium IVH199/18 sodiumEsomeprazole (as sodium)L2C9GWQ43HDTXSID90904644RefChem:55133DTXCID6013337731H-BENZIMIDAZOLE, 6-METHOXY-2-((S)-((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT (1:1)1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)(s)-omeprazole sodium salt
名称をさらに表示
(S)-オメプラゾールナトリウム塩エスオメプラゾールナトリウムエソメプラゾールナトリウム(S)-オメプラゾールナトリウムEsomeprazole NaNexium sodiumEsoMeprazole sodEsomeprazoleandsalts(S)-OMeprazole sodiuMEsomeprazole Sodium D3ESOMEPRAZOLE NA (34-37%)Esomeprazole sodium - EP
Esomeprazole (sodium)Esomeprazole Sodium [USAN]Esomeprazole sodium (USAN)6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Sodium Salt; (S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ideEsomeprazole sodium?Nexium IV (TN)Esomeprazole sodium CRS

物性

構造計算による物性

極性表面積
81.5 Ų
水素結合供与体数
0
水素結合受容体数
7
回転可能結合数
5
重原子数
25
形式電荷
0
複雑度
459

実験および物理化学的性質

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
156 °C · 156 °C (approx)
貯蔵温度
-20 °C · Inert atmosphere,Store in freezer, under -20°C
溶解性
DMSO(微量、超音波処理)、メタノール(微量)、水(微量)
外見
個体
色
ペールベージュからブラウン
安定性
吸湿性
InChI
InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1
InChIKey
RYXPMWYHEBGTRV-UHFFFAOYSA-N
SMILES
C1(S(=O)CC2=NC=C(C)C(OC)=C2C)N([Na])C2=C(C=C(C=C2)OC)N=1

化学的性質

化学的特性Beige Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (83.3%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (83.3%)

毒性情報

Health Effects · 2 件

Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid heartbeat, sweating.

may include bone rebuild interference and B12 vitamin reduction. [Wikipedia]

Exposure Routes · 2 件

Oral

The delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable.

化学と産業

薬理情報

Metabolism/Metabolites · 2 件

Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome P450 system via CYP2C19 and CYP3A4. Metabolism produces inactive hydroxy and desmethyl metabolites, which have no effect on gastric acid secretion. Less than 1% of the parent drug is excreted in urine. Route of Elimination: Approximately 80% of the administered dose of esomeprazole is excreted as metabolites in urine and the remaining 20% is excreted in feces. Half Life: 1-1.5 hours

Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME). Route of Elimination: Urinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces. Half Life: 0.5-1 hour (healthy subjects, delayed-release capsule); 3 hours (hepatic impairment)

FDA Pharmacological Classification · 2 件

ESOMEPRAZOLE SODIUM

Proton Pump Inhibitors [MoA]; Cytochrome P450 2C19 Inhibitors [MoA]; Proton Pump Inhibitor [EPC]

MeSH Pharmacological Classification · 2 件

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.

用途と製造

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
161796-78-7
PubChem CID
23674541
ChEMBL
CHEMBL1200470
UNII
L2C9GWQ43H
EC Number
620-470-6
Toxicity Summary · 2 件

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

Signs and Symptoms · 2 件

Blurred vision, confusion, drowsiness, dry mouthflushingheadache, nausea, rapid heartbeat, sweating.

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

Carcinogen Classification · 2 件

No indication of carcinogenicity to humans (not listed by IARC).

No indication of carcinogenicity to humans (not listed by IARC).

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Esomeprazole sodium

vLess-DILI-concern

4

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

安全データ

wgk
WGK 3
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 2Eye Irrit. 2Skin Sens. 1
ストレージクラス
11 - Combustible Solids
Uses · 2 件

Used in the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. Used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. [Wikipedia]

Omeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.

応用分野 · 1 件

使用Esomeprazole sodium is a commonly used anti-ulcer drug. It was successfully developed by AstraZeneca for the first time. It is a proton pump inhibitor. The drug of choice for related diseases. (S)-Omeprazole is the (S)-enantiomer of Omeprazole (O635000) a gastric proton-pump inhibitor. (S)-Omeprazole is more potent that its (R)-enantiomer and is used in the treatment of gastroesophageal ref lux disease as well as gastrointestinal ulcers associated with Crohn's disease.